ClinicalTrials.Veeva

Menu
S

Skin Cancer and Dermatology Institute | Sparks Location

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BFB759

Parent organization

This site is a part of Skin Cancer and Dermatology Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 2 total trials

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis (COMPASS 2-AD)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB75...

Enrolling
Atopic Dermatitis (AD)
Biological: BFB759
Drug: Placebo

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period...

Enrolling
Hidradenitis Suppurativa (HS)
Biological: Tibulizumab Dose B
Other: Placebo

Trial sponsors

B
Z

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems